PharmaCorp Rx Shares Outstanding
The The number of shares of PharmaCorp Rx (PCRX.V) as of Oct 20, 2026 is 174.08 M. In the previous year, The number of shares was 174.08 M — a change of 0.00% (lower).
Get this data via API
Financial Data API
Shares Outstanding
174.08 M
YoY
0.00%
Last updated:
In 2025, PharmaCorp Rx had 174.08 M outstanding stocks, a 0.00% change from the 174.08 M stocks in the previous year.
The PharmaCorp Rx Shares Outstanding history
3 Years
10 Years
25 Years
Max
| YEAR | Shares Outstanding | YoY |
|---|---|---|
| est | 117.30 | 0.00% |
| est | 117.30 | -100.00% |
| 174.08 M | 0.00% | |
| 174.08 M | 0.00% | |
| 174.08 M | 0.00% | |
| 174.08 M | 0.00% | |
| 174.08 M | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
PharmaCorp Rx Number of shares
PharmaCorp Rx shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
PharmaCorp Rx Stock analysis
Shares Outstanding Details
Evaluating PharmaCorp Rx's Shares Outstanding
PharmaCorp Rx's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in PharmaCorp Rx’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding PharmaCorp Rx’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in PharmaCorp Rx’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about PharmaCorp Rx stock
The number of shares of PharmaCorp Rx is 174.08 M in 2025.
The number of shares of PharmaCorp Rx changed from 174.08 M to 174.08 M, representing a 0.00% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of The number of shares PharmaCorp Rx since 2006 – with annual values, charts, and detailed analysis.
The number of shares indicates the total number of a company's shares. This includes not only the shares available on the market, but also the shares held by shareholders and the shares retained by the company.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Other — PharmaCorp Rx
All Key Metrics — PharmaCorp Rx
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth